Cardioprotective Effects of Exenatide in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention | Zendy

Jong Shin Woo | Zendy; Weon Kim | Zendy; Sang Jin Ha | Zendy; JinBae Kim | Zendy; Soo–Joong Kim | Zendy; Woo-Shik Kim | Zendy; Hyun Ju Seon | Zendy; Kwon Sam Kim | Zendy

Open Access

Cardioprotective Effects of Exenatide in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Author(s) -

Jong Shin Woo,

Weon Kim,

Sang Jin Ha,

JinBae Kim,

Soo–Joong Kim,

Woo-Shik Kim,

Hyun Ju Seon,

Kwon Sam Kim

Publication year - 2013

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.113.301586

Subject(s) - exenatide , medicine , percutaneous coronary intervention , myocardial infarction , cardiology , ejection fraction , thrombolysis , troponin , heart failure , diabetes mellitus , endocrinology , type 2 diabetes

Experimental evidence suggests that exenatide, a glucagon-like peptide 1 receptor analogue, has significant cardiovascular protective effects in various conditions. We examined whether routine use of exenatide at the time of primary percutaneous coronary intervention would reduce infarct size in patients with ST-segment-elevation myocardial infarction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research